Bio Refine

Company Overview

Snapshot

Founded in July 2019 by Boaz Shenhav, Bio Refine operates with 1–10 employees. The company has raised $900K across two funding rounds from one investor.

Business overview

Bio Refine is a Health Tech & Life Sciences company focused on developing an endovascular annuloplasty remodeling system for the repair of mitral and tricuspid heart valves. This implantless solution aims to provide treatment for patients who are currently unable to undergo open surgery due to high risks. The technology offers a safe, repeatable, and implant-free procedure using a standard endovascular approach, which also simplifies regulatory processes and does not preclude ancillary procedures. Bio Refine operates within the Medical Devices sector, specifically targeting Medical Treatment & Therapeutics, and serves the Healthcare industry, particularly providers.

Company Intelligence Q&A

What is Bio Refine's core technology?

Bio Refine has developed an endovascular annuloplasty remodeling system designed for the repair of mitral and tricuspid heart valves without the need for an implant.

When was Bio Refine founded and by whom?

Bio Refine was founded in July 2019 by Co-Founder & CEO Boaz Shenhav.

What is the primary benefit of Bio Refine's solution?

The implantless solution offers a safe, repeatable, and implant-free procedure that uses a standard endovascular approach, making it suitable for patients who cannot undergo high-risk open surgery.

What was the initial funding Bio Refine received?

In February 2023, Bio Refine received $900,000 in Pre-Seed funding from Peregrine Ventures.